Navigation Links
DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of,Improved Glycemic Control and Significant Reductions of,LDL-Cholesterol and C-Reactive Protein

/p>

DIO-902 is an oral, once-daily drug being developed for the treatment of type 2 diabetes. It is a single enantiomer of racemic ketoconazole which suppresses cortisol production by inhibiting the 11 beta hydroxylase enzyme, the terminal step in the adrenal synthesis of cortisol. This novel mechanism of action makes DIO-902 a first-in-category cortisol inhibitor.

"Our unique approach to inhibition of cortisol synthesis offers the potential to address one of the underlying causes of type 2 diabetes, as well as multiple co-morbidities associated with both the disease, and its precursor, metabolic syndrome," said David A. Cory, Chief Executive Officer of DiObex, Inc. "DIO-902 offers patients the promise of effectively managing glycemia and lipids with a single medication. We are excited about the preliminary data generated to date and are rapidly progressing DIO-902 to the next stage of clinical development."

Data from various preclinical, epidemiological and clinical studies have suggested that a link exists between high cortisol levels and visceral adiposity, insulin resistance, and hyperglycemia -- common elements of the metabolic syndrome and type 2 diabetes.

The two-week trial with DIO-902 enrolled 37 patients with type 2 diabetes who were randomized to placebo, three different doses of DIO-902 ( 200 mg, 400 mg and 600 mg) or ketoconazole. Patients were either drug naove or on metformin, and had lipid-lowering agents washed out for at least 21 days prior to the first dose of the study drug. No serious adverse effects related to the study drug were reported. Liver function tests were carefully monitored, and no clinically meaningful changes were observed in any of the treated subjects. In fact, a number of subjects enrolled with mild transaminase elevations normalized during the two week treatment.

DiObex will conduct a multi-center, 16-week, phase 2b dose-ranging study with DIO-902; this study is scheduled to start enrolling patien
'"/>




Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
11. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
Post Your Comments:
(Date:12/1/2008)...ewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (...t , one of the world,s leading medical journals, r...egulator, experimental compound tasimelteon (VEC-1...titled "Melatonin agonist tasimelteon (VEC-162) fo...andomised controlled multicentre trials." Results ...
(Date:12/1/2008)...swire/ -- Roche announced today that a,comparativ...ived pain and,discomfort associated with blood gl...toring systems and lancing devices were deemed lea...ll, the ACCU-CHEK Aviva and ACCU-CHEK Compact,Plu...EK Multiclix, ACCU-CHEK,Softclix and ACCU-CHEK So...
(Date:12/1/2008)...he best policy , , ROCHESTER, Minn., Dec. ... Clinic finds the use of the drug therapy etanerce... acute inflammation of the liver caused by excessi...y are published in the December issue of Gastroen... , VIDEO ALERT: Additional audio and video res...
(Date:12/1/2008)...d for Tuesday, December 9 at 11:00 am ET to Discus...H SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-Firs... SNSS ), a biopharmaceutical company focused on th...y therapeutics, today announced new data from its ...L) will be presented during the 50th American Soci...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3ASPH and APHA Collaborate to Shore up the Public Health Workforce Pipeline 3A 27906 1ASPH and APHA Collaborate to Shore up the Public Health Workforce Pipeline 3A 27906 2ASPH and APHA Collaborate to Shore up the Public Health Workforce Pipeline 3A 27906 3Bright Horizons Congratulates 76 Clients Named to Working Mothers 100 Best 27901 1Bright Horizons Congratulates 76 Clients Named to Working Mothers 100 Best 27901 2Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards 3355 1Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards 3355 2Scientists unveil mechanism for up and down in plants 5605 1Scientists unveil mechanism for up and down in plants 5605 2
...etary DNA delivery technology enables sustained,In...es,atherosclerosis progression in mouse model of h..., 2007 - Research conducted,at Cleveland Clinic an...ology,s 58th Annual Scientific Session showed that...inflammatory protein,interferon-beta (IFN-beta) us...
...oadministered with statins for only five weeks at,...hieved with,statins alone, with similarly favorabl... and CARLSBAD, Calif., March 26, 2007,/PRNewswire-... new,results from its Phase 2 clinical trial of IS...day at the of Cardiology,Annual Scientific Session...
Other Medicine Technology:Interferon Beta DNA Treatment Delivered with Ichor Technology,Reduces Atherosclerosis Progression in Mice 2Interferon Beta DNA Treatment Delivered with Ichor Technology,Reduces Atherosclerosis Progression in Mice 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 2Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 4Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 6Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 7Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 8Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 9
(Date:12/2/2008)...irstCall/ -- Neuralstem Inc.,(NYSE Alternext US: ...ollaboration with the China Medical University &am...Neuralstem,s human spinal cord neural stem cell,t...phic Lateral Sclerosis (ALS,or Lou Gehrig,s disea...,investigator. , (Logo: http://www.newscom...
(Date:12/2/2008)...ia-FirstCall/ -- China Sky One Medical,Inc. ("Ch...CSKI ), a leading,fully integrated pharmaceutical...People,s Republic of China ("PRC"), announced toda...f Financial Officer and Secretary and will,also s...aces Yu-kun Zhang, who,had served as interim CFO ...
(Date:12/2/2008)...Call/ -- Mylan Inc. (NYSE: MYL ) today,announce...s Inc., have entered,into a settlement agreement ...p. and Novartis International AG related to Letroz...ara(R). , Mylan,s Vice Chairman and CEO Rob...ave reached this agreement, which demonstrates our...
(Date:12/2/2008)...ire/ -- In response to the commentary entitled "Co...ory Infections, and the Vitamin D Deficiency Epide...upplement experts, Nordic Naturals announced today... compromise to consumers and actually offer health...al Vitamin A. According to Karin Yien, MD, Nordic ...
Breaking Medicine News(10 mins):Health News:Neuralstem Collaborates with Hospital in Taiwan to Develop Additional ALS Stem Cell Clinical Trials 2Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 2Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 3Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2Health News:Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy 2
...uta of the Salvation Healing Ministry, who is a se...rt on charges of swindling six people of Sh1.6 mil...le that they would be cured of HIV/AIDS through pr...te, Margaret Muigai, denied her bail since Central...
...acco by youngsters will cost their dear lives and ...people a year, which will greatly affect the count...me to over 250 million tobacco users and more than...ated diseases every year. But the most ominous sig...
...l carried out to treat diabetic nerve damage has s...vered by researchers// of the University of Manche...to trigger a particular gene responsible to preven...tic neuropathy. The positive preclinical results...
...spitals revealed falling standards of cleanliness .... Comparing to 56 percent people in 2002, only 52...y about 51 percent in 2003 said lavatories were ve.... Contradicting the above, the annual NHS patients...
Other Medicine News:Health News:Tobacco Consumption By Youths Will Hamper India’s Economic Growt 2Health News:New Gene Therapy Treats Diabetic Neuropathy 2
...ducts are offered as 1-piece or modular, in regula...ay be customized with handles of choice and other ...ts. Many standard patterns are available from Medi...ivery times. , Please Note: Individual instrumen...
...ducts are offered as 1-piece or modular, in regula...ay be customized with handles of choice and other ...ts. Many standard patterns are available from Medi...ivery times. , Please Note: Individual instrumen...
...ducts are offered as 1-piece or modular, in regula...ay be customized with handles of choice and other ...ts. Many standard patterns are available from Medi...ivery times. , Please Note: Individual instrumen...
The Featured Products are kept in stock at Mediflex and are offered as 1-piece or modular in regular or extra long lengths. All come equipped with insulation, flush ports, rotating shafts, ratchets (
Medicine Products: